Resection of brain lesions with a neuroendoscopic ultrasonic aspirator — a systematic literature review

Florian Ebel · Ladina Greuter · Raphael Guzman · Jehuda Soleman

Received: 26 May 2022 / Revised: 27 June 2022 / Accepted: 15 July 2022 / Published online: 27 July 2022
© The Author(s) 2022

Abstract
The development of minimally invasive neuroendoscopy has advanced in recent years. The introduction of the neuroendoscopic ultrasonic aspirator (NUA) increased the treatment spectrum of neuroendoscopy. This review aimed to present a systematic overview of the extent of resection, lesion characteristics, technical aspects, complications, and clinical outcomes related to using the NUA. Articles were identified by searching the PubMed/Medline, Embase, and Web of Science database through June 2022 with restriction to the last 20 years. We included case series, case reports, clinical trials, controlled clinical trials, meta-analyses, randomized controlled trials, reviews, and systematic reviews written in English. Studies reporting on endonasal approach or hematoma evacuation using the NUA were excluded. The references of the identified studies were reviewed as well. Nine full-text articles were included in the analysis, with a total of 40 patients who underwent surgery for a brain tumor using NUA. The most common underlying pathology treated by NUA was colloid cyst (17.5%), pilocytic astrocytoma (12.5%), subependymal giant cell astrocytoma (7.5%), subependymoma (7.5%), and craniopharyngioma (7.5%). Complete or near-total resection was achieved in 62.5%. The most frequently reported postoperative complication was secondary hydrocephalus (10%), meningitis/-encephalitis (7.5%), cognitive impairment (7.5%), and subdural hygroma (7.5%). In one case (2.5%), surgery-related death occurred due to a severe course of meningoencephalitis. According to the preliminary data, NUA seems to be a safe and efficient minimally invasive alternative to conventional microscopic resection of brain tumors. Further studies to investigate advantages and disadvantages of using the NUA are needed.

Keywords Neuroendoscopy · Oncology · Ultrasonic aspirator · Surgical technique

Introduction
Neuroendoscopy has become a valuable and important instrument for treating various neurosurgical pathologies in recent decades [1]. Before introducing neuroendoscopic ultrasonic aspirators (NUA), and other suction devices like the NICO Myriad (NICO Corp., Indianapolis, USA) and Artemis (Penumbra, Alameda, USA), the fields of application for neuroendoscopy were limited to the treatment of hydrocephalus, biopsies, or partial resection of brain lesions [2]. The first ultrasonic aspirator (UA) application for open neurosurgical procedures was described in 1978 [3]. There were numerous modifications and further improvements to the UA in the following years.

Initially, animal experiments were carried out, which showed good and safe handling, whereon NUA was used for the first time in five clinical cases in 2008 [2]. The technical possibilities are currently still limited, but NUA has led
to progress in the endoscopic resection of intraventricular brain lesions.

To the best of our knowledge, this is the first systematic literature review focusing on the use of NUA for the resection of brain lesions. This review aimed to present a systematic overview of the extent of resection, tumor characteristics, technical aspects, complications, and clinical outcomes related to using NUA.

**Methods**

The systematic literature search was carried out following the updated PRISMA Guidelines 2020 [4]. The literature database PubMed/Medline, Embase, and Web of Science was searched, and appropriate clinical studies published before 14.06.2022 were identified.

We used a search term with the keywords “neuroendoscopy & endoscopy,” “ultrasonic aspirator,” and “neurosurgery” in the PubMed/Medline, Embase, and Web of Science databases with restrictions to English language (Fig. 1). We included case series, case reports, clinical trials, controlled clinical trials, meta-analyses, randomized controlled trials, reviews, and systematic reviews that reported cases in which brain tumors were resected neuroendoscopically by NUA. Studies reporting on the endonasal use or hematoma evacuation using the NUA were excluded.

Two authors (F.E. and J.S.) independently assessed all results for eligibility. Where consensus opinion could not be reached, a third researcher was to be consulted (R.G.). First, all duplicates were excluded. Then, the titles and afterwards the abstracts were analyzed. The remaining studies were then included in the full-text analysis. All included full-text studies underwent independent quality assessment (F.E. and J.S.) using the Joanna Briggs Institute (JBI) Critical Appraisal Checklist [5]. All nine included full-text studies met the quality criteria of the JBI checklist and none had to be excluded.

As outcome parameters, we primarily analyzed the extent of resection (EOR) and secondarily the various tumor characteristics, and intraoperative and postoperative complications, as well as the recurrence rate at the resection site, clinical outcome during follow-up, and technical aspects. In the article of Spennato et al., only the tumor volume (cm³) was reported. To compare it with the other included studies, we approximately converted the volume (v) into a diameter (d) using the formula \( d = \sqrt[3]{2 \times v} \). To simplify the data presentation, we divided the EOR into three groups and defined them as follows: gross total resection (GTR) as a complete resection without evidence of a residual tumor on postoperative imaging, near total resection (NTR) with a minimal tumor remnant (>95% resection extent), and subtotal resection (STR) if larger remnants were left in situ during surgery.

**Statistical analysis**

All analyses were done using the SPSS Software (Version 28, IBM Corp., New York, USA). Univariate analysis was done using the Fisher exact or chi-square test for categorical data and Mann–Whitney U or the Kruskal–Wallis test for continuous data. A value of \( P < 0.05 \) was considered significant.

**Results**

A total of 121 studies were identified during the systematic literature search. Additionally, one study based on reference search was added. After excluding 43 duplicates, 79 articles were reviewed, and 62 were excluded based on the title and abstract. Of the 17 full texts reviewed, we excluded a total of eight studies due to various reasons (Fig. 2) [6–13]. This finally resulted in nine studies, which we included in the analysis (Fig. 2) [2, 14–21]. These studies consisted of 6 case series [2, 15, 18–21] and three case reports [14, 16, 17]. A total of 40 patients were analyzed in the included studies, of whom 19 (47.5%) were children (Table 1). The mean patient age was 25 years (±23.5, range 0.42–74), and 64.9% were men.

**Extent of resection**

Of the nine studies, seven (77.8%) reported on the extent of resection [14, 15, 17–21] (Table 1). Information about the EOR was available in 38 (95%) patients. GTR/NTR
was achieved in 62.5%. No significant differences in lesion size, tumor type, and tumor location were observed between patients who underwent GTR/NTR and STR, respectively (Table 2).

### Tumor characteristics

All studies included in the quantitative analysis reported on tumor type. The exact tumor location was reported by eight
studies (88.9%) [14–21]. Tumor size was reported only by five studies in 23 of 40 cases (57.5%) [16, 17, 19–21]. Of the 40 tumors resected by NUA, the most frequent were colloidal cysts (17.5%), pilocytic astrocytomas (12.5%), subependymomas (7.5%), and craniopharyngiomas (7.5%) (Table 2). Tumor location was intraventricular in 34 cases (85%), tectal in three cases (7.5%), and thalamic in two cases (5%). The mean tumor size was 24.6 (±11.2 mm, range 9 to 45 mm).

### Technical aspects

In all included studies, the use of the NUA from Söring (Endoscopic Neurosurgical Pen, Söring GmbH, Quickborn, Germany) was described [2, 14–21]. Eight studies (88.9%) described the endoscope used and six studies (66.7%) reported their endoscopes’ angulation [2, 15–21]. Most frequently (77.5%), the Gaab rigid endoscope (Karl Storz GmbH, Tuttinglen, Germany) was used. In four cases (10%), the InVent endoscope (Aesculap, Inc., Tuttinglen, Germany) was used alternatively (Table 3). A 0° endoscope was used in 21 cases (52.5%) and a 30° endoscope in 2 cases (5%). In 12 cases where a Gaab rigid endoscope was used, the angulation of the endoscope was not described [18].

In 90% of the reported cases, a purely endoscopic procedure was performed [2, 14–19, 21]. In the remaining 10% of cases, the surgery was converted to an open microscopic procedure [20]. All studies reported the surgical access [2, 14–21]. The most common approach was a frontal approach (87.5%), either precoronal or at the frontal hairline [2, 14–16, 18–21]. In five cases (12.5%), a posterior approach was performed [17, 18, 20] (Table 3). One study by Cinalli et al. described using a thulium laser (RevoLix Jr, LISA Laser Germany) for coagulation [18]. The remaining studies used mostly monopolar electrocautery or moderate irrigation for

---

**Table 2** Overview of the different tumor characteristics in total and divided into the groups gross total/near total and subtotal resection

| Lesion size (mm) | No. of studies reported (%) | No. of patients (%) | GTR/NTR | STR | p |
|------------------|-----------------------------|---------------------|---------|-----|---|
| 5/9 (55.6)       | 24.6 ± 11.2                 | 22.9 ± 11.1         | 28.8 ± 11.4 | 0.259 |
| Types of tumor   | 9/9 (100)                   |                     |         |     |   |
| Colloid cyst     | 7 (17.5)                    | 5 (20)              | 1 (7.7) |     |   |
| Pilocytic astrocytoma | 5 (12.5)                |                     |         |     |   |
| SEG A            | 3 (7.5)                     | 3 (12)              |         |     |   |
| Subependymoma    | 3 (7.5)                     | 3 (12)              |         |     |   |
| Craniopharyngioma| 3 (7.5)                     | 2 (8)               |         |     |   |
| Low grade intraparentricular tumor | 2 (5)               | 1 (4)               | 1 (7.7) |     |   |
| Meningioma       | 2 (5)                       | 2 (8)               |         |     |   |
| Glioma (unclear dignity) | 2 (5)                | 1 (4)               | 1 (7.7) |     |   |
| Pilomyxoid astrocytoma | 2 (5)                   |                     |         |     |   |
| Papillary tumor of pineal region | 1 (2.5)                | 1 (4)               |         |     |   |
| Pineal anlage tumor | 1 (2.5)                  |                     |         |     |   |
| Atypical plexus papilloma | 1 (2.5)                |                     |         |     |   |
| Neurocytoma       | 1 (2.5)                     |                     |         |     |   |
| Glioneuronal tumor | 1 (2.5)                  |                     |         |     |   |
| Choroid plexus carcinoma | 1 (2.5)                |                     |         |     |   |
| Medulloblastoma   | 1 (2.5)                     |                     |         |     |   |
| Epidermoid        | 1 (2.5)                     |                     |         |     |   |
| Atypical teratoid rhabdoid tumor | 1 (2.5)               |                     |         |     |   |
| Teratoma          | 1 (2.5)                     |                     |         |     |   |
| Astrocytoma grade 2 | 1 (2.5)                   |                     |         |     |   |
| Tumor location    | 8/9 (88.9)                  |                     |         |     |   |
| Third ventricle   | 19 (47.5)                   | 9 (36)              | 9 (69.2) |     |   |
| Lateral ventricle | 14 (35)                     | 12 (48)             | 2 (15.4) |     |   |
| Tectum            | 3 (7.5)                     | 2 (8)               | 1 (7.7)  |     |   |
| Thalamus          | 2 (5)                       | 1 (4)               | 1 (7.7) |     |   |
| Aqueduct of sylvius | 1 (2.5)                   |                     |         |     |   |

No. number, GTR gross total resection, NTR near total resection, STR subtotal resection, SEG A subependymal giant cell astrocytoma
hemostasis. In addition to resection of the lesion, intraoperative septostomy (15%), endoscopic third ventriculostomy (12.5%), and an external ventricular drainage insertion (7.5%) were performed as well (Table 3).

Complications and follow-up

All included studies reported on perioperative complications [2, 14–21]. The most common intraoperative complications reported were bleeding (7.5%), loss of vision due to ruptured colloid cyst or air bubbles produced by the NUA (5%), and abrasion of the fornix (5%). Overall, 13 patients (32.5%) had at least one postoperative complication. The most common postoperative complications were secondary hydrocephalus (10%), meningitis/meningoencephalitis (7.5%), cognitive impairment (7.5%), and subdural hygroma (7.5%). All three cases reported with cognitive impairment were transient and completely regressed during follow-up [20]. In all cases of meningitis or meningoencephalitis, which were diagnosed based on clinical signs and altered CSF parameters, cultures remained sterile [16, 19, 20]. The patients who developed subdural hygromas and secondary hydrocephalus were treated by subduroperitoneal shunt (n = 2) and a ventriculoperitoneal shunt (n = 5), during the postoperative course [17–21]. In the included studies, no permanent morbidity was reported.

Seven of the nine studies (77.8%) described follow-up duration which averaged 16.4 ± 15.5 months [14, 16–21]. Clinical course during follow-up was reported by only 33.3% (n = 3) of the studies [15, 17, 20]. In 20% of the patients, preoperative symptoms improved during follow-up, and in 10% of patients, no symptoms were present. Information regarding the occurrence of recurrence was available in 66.7% of studies [14, 17–21]. In 40% of the patients, there was no recurrence. In 22.5%, the tumor residue left intraoperatively was radiologically stable, and in eight cases (20%), there was tumor progression during follow-up. Three patients died due to tumor progression 6 and 7 months after total resection of an intraventricular medulloblastoma located in the frontal horn, an atypical teratoid rhabdoid tumor of the third ventricle and after STR of a pilomyxoid astrocytoma of the third ventricle [18, 21]. One patient, who showed tumor progression

| Type of NUA            | No. of studies reported (%) | No. of patients (%) |
|-----------------------|-----------------------------|---------------------|
| ENP (Söring GmbH)     | 9/9 (100%)                  | 40 (100)            |

| Type of endoscope*    | No. of studies reported (%) | No. of patients (%) |
|-----------------------|-----------------------------|---------------------|
| 0° Gaab rigid         | 8/9 (88.9%)                 | 18 (45)             |
| 30° Gaab rigid        | 1 (2.5)                     |                     |
| Gaab rigid (angulation not available) | 12 (30) | |
| 0° InVent             | 3 (7.5)                     |                     |
| 30° InVent            | 1 (2.5)                     |                     |

| Add. using microscope| No. of studies reported (%) | No. of patients (%) |
|----------------------|-----------------------------|---------------------|
| No                   | 9/9 (100%)                  | 36 (90)             |
| Yes                  | 4 (10)                      |                     |

| Type of approach      | No. of studies reported (%) | No. of patients (%) |
|-----------------------|-----------------------------|---------------------|
| Precoronal            | 9/9 (100%)                  | 29 (72.5)           |
| Frontal hairline      | 6 (15)                      |                     |
| Posterior parietal    | 5 (12.5)                    |                     |

| Add. Intraoperative procedure | No. of studies reported (%) | No. of patients (%) |
|------------------------------|-----------------------------|---------------------|
| Septostomy                   | 9/9 (100%)                  | 6 (15)              |
| ETV                          | 5 (12.5)                    |                     |
| EVD                          | 3 (7.5)                     |                     |
| Rickham and ventricular catheter | 1 (2.5) |   |
| Septostomy and EVD           | 1 (2.5)                     |                     |
| Septostomy and ETV           | 1 (2.5)                     |                     |
| Septostomy and foraminoplasty | 1 (2.5)                     |                     |

No, number, NUA neuroendoscopic ultrasonic aspirator, ENP endoscopic neurosurgical pen, Add. additionally, SEGA subependymal giant cell astrocytoma, ETV endoscopic third ventriculostomy, EVD external ventricular drain

*In the case series by Spennato et al., it is described that in the 4 patients, either the Gaab or the InVent endoscope was used. No further specification was made.
of a craniopharyngioma underwent open microsurgery 6 months after neuroendoscopic STR [18]. One patient showed recurrence following totally resected pineal anlage tumor, after which he received chemotherapy [18]. Two patients are described, who underwent open microsurgical tumor resection one month after neuroendoscopic STR of an immature teratoma of the pineal region and 3 months after STR of a thalamic low-grade glioneuronal tumor, respectively [18]. In the case series of Spennato et al. all patients showed tumor progression after STR of pilomyxoid or pilocytic astrocytoma. Three of four patients underwent open microsurgical resection for tumor progression during follow-up. One patient underwent a second endoscopic tumor resection for tumor progression 8 months postoperatively [21]. Overall, one case (2.5%) reported by Desse et al. resulted in surgical mortality due to extensive meningoencephalitis after a colloid cyst ruptured intraoperatively [16] (Table 4).

### Discussion

Based on this systematic review, colloid cysts and pilocytic astrocytomas were most frequently resected by NUA, and GTR/NTR was obtained in the majority of cases. Permanent morbidity did not occur.

### Tumor characteristics

Selvanathan et al. was the first to describe the use of NUA for neuroendoscopic resection of solid tumors [14]. Cinalli et al. showed that the endoscopic removal of brain tumors is not limited to intraventricular tumors but can also be applied to solid tumors such as SEGAs or craniopharyngiomas that are located suprasellar or paraventricular [18]. Further, in the work of Oertel et al., NUA was successfully used for the resection of pituitary adenomas [2]. Resection of solid tumors using NUA requires careful adaptation of...
the consistency, cavitation intensity in the case series of Ibanez et al. was between 60 and 80% for solid tumors [19]. For soft colloid cysts, the intensity was reduced to 20%. Based on our experience for soft lesion such as colloid cyst, an intensity of 20–30% is sufficient and safe, while for solid lesions (e.g., meningiomas), the intensity needs to be risen to 70–80% [20]. According to the literature, the use of the NUA for neuroendoscopic tumor resection is particularly suitable for smaller (< 2 cm) and soft tumors with a poor vascularization [18, 20]. The use of the NUA is not suitable for very hard tumors such as teratomas [18]. Differences between GTR/NTR and STR in terms of lesion size, tumor type and location were not found in this study (Table 2). Out of the 13 (32.5%) patients with lesions larger than 2 cm, in seven patients a GTR could be achieved using a pure endoscopic or an endoscopic-assisted approach in 77.8% and 22.2%, respectively. Furthermore, in five (38.4%) patients with lesions larger than 2 cm transient complications, such as cognitive impairment, meningitis with consecutive secondary hydrocephalus and postoperative hygroma occurred (results not shown).

Endoscopic versus microscopic resection of intraventricular lesions

There are different access techniques to reach intra- or para-ventricular lesions. Depending on the surgical technique, whether a pure endoscopic, an endoscopic-assisted, or a microscopic resection is desired, different approaches and techniques are chosen, which are associated with different advantages and disadvantages. Pure microscopic approaches to the third or lateral ventricle can be divided into two major categories: transcortical and interhemispheric/transcallosal [22].

Milligan et al. presented a series of 127 patients with intraventricular tumors, 75 of whom were operated through a transcallosal approach and 52 through a transcortical approach. The most common lesions were colloid cysts, pilocytic astrocytomas, meningiomas, and diffuse astrocytomas. Overall, the mean tumor diameter was 3 ± 1.7 cm. GTR or NTR was achieved in 87% of cases and was comparable between the two different approaches. At least one postoperative complication occurred in 88 (69%) patients. Aphasia/abulia, cognitive impairment, hemiparesis and epileptic seizures were the most common postoperative complications. At the last follow-up, most patients recovered from the initial postoperative deficits, with 23.6% having persistent impairments [22].

A meta-analysis by Sayehmiri et al. compared microscopic and endoscopic resection of colloid cysts. They could show that microscopic resection was associated with higher GTR rates (98.15% versus 91.29%), and a lower risk of recurrence compared to endoscopic colloid cyst resection. However, the postoperative complication rate in patients with endoscopic resection was significantly lower compared to microscopic resection (10.42% versus 20.68%) [23]. A further meta-analysis showed similar results with a significantly lower morbidity rate associated with endoscopic colloid cyst resection (10.5% versus 16.3%) [24]. The most common complications in the microscopic group were cognitive impairment (5.1%), seizures (4.3%), and venous infarction (2.1%) and in the endoscopic group cognitive impairment (5%), meningitis (2.7%) and intraventricular hemorrhage (1.2%) [24].

Based on our systematic review, GTR or NTR was achieved in 62.5% using NUA. Compared to the abovementioned literature, this is below the rate of 87% achieved in microscopic resection of intraventricular lesions [22]. In contrast, transient morbidity of 32.5% found in our study, appears to be significantly lower than the 69% morbidity reported for microscopically resected intraventricular tumors [22]. One of the most frequent transient complications mentioned in our review is meningitis, although in all cases the cultures remained sterile. This could possibly indicate the presence of chemical meningitis instead of a bacterial meningitis, which has been described in the literature after neurosurgical procedures as well [25]. Despite the introduction of the NUA, which has expanded the treatment spectrum of neuroendoscopy, the options in neuroendoscopic surgery are still limited. As published in a previous study of our group, the characteristics such as size, vascularization, consistency, and architecture of the tumor can be used to estimate whether the tumor is suitable for pure neuroendoscopic resection or not [20]. Due to the limited room for maneuver during neuroendoscopic surgery, the selection of suitable tumors is essential. The advantage of neuroendoscopy is the minimal invasiveness, which, as expected, is also reflected in a reduced morbidity compared to microscopically resected tumors.

Overall, both techniques certainly have their advantages and disadvantages and depending on the factors mentioned as well as the surgeon’s experience with the respective technique the appropriate surgical approach must be carefully selected on an individual basis.

Technical aspects

One of the technical challenges while using NUA is that intermittently, intraoperative visibility can be significantly reduced for various reasons. Air bubbles may occur secondarily due to the cavitation effect due to rapid movement [14]. This can be prevented by continuous irrigation. Cyst rupture can lead to a sudden loss of vision [16]. Furthermore, bleeding can severely restrict vision or cause a complete loss of vision. To control minor bleeding, extensive irrigation is...
A careful selection of the patients to be operated by NUA is essential. The instruments for neuroendoscopic tumor resection are continuously evolving, and we expect that the learning curve will be steep. The systematic literature review showed that in 62.5% a GTR/NTR could be achieved with an overall transient morbidity rate of 32.5% and no permanent morbidity. Our systematic literature review showed that in 62.5% a GTR/NTR could be achieved with an overall transient morbidity rate of 32.5% and no permanent morbidity.

**Future perspectives**

It can be challenging to keep one’s orientation during neurosurgical operations, especially tumor resection. There are several commercially established navigation systems. Preoperatively, important structures can be color-coded and displayed intraoperatively. The microscope can also be navigated, and it is possible to have the marked structures displayed in augmented reality when looking through the microscope into the operating field. Navigating the endoscope is possible but projecting the different anatomical structures or the tumor to the endoscopy screen is currently unavailable. Augmented reality could potentially be used in neuroendoscopy in the future, making navigation easier and ultimately making minimally invasive neurosurgery safer.

Furthermore, the angled endoscopes allow us to gain insight into areas that remain hidden with the microscope. Unfortunately, there are currently no commercial ultrasound aspirators with an angled or controllable flexible tip. Since the angle of entry of the speculum limits the movement of the ultrasound aspirator, it is not always possible to reach these areas. With an angled tip of the UA, such regions could be reached better. A robotic flexible tip that can be controlled would be ideal for better maneuvering around the tumor during its resection. It would be even more effective to resect large tumors with complicated configurations with an angled or flexible tip of the ultrasound aspirator. In addition, Söring’s ultrasonic aspirator for open neurosurgical tumor resections was recently introduced with an extension for intraoperative neuromonitoring. This allows intraoperative subcortical mapping, which can significantly increase tumor resection’s safety. Unfortunately, such systems are not available for NUA yet. This would be an advantage for neuroendoscopic tumor surgery around eloquent areas such as the thalamus and other periventricular structures. Furthermore, endoscopic bipolar forcesps would be very helpful, where the tips can be spread, and thus targeted coagulation of vessels would be possible. Finally, an endoscopic aspirator, with which targeted suction would be possible, would aid significantly in neuroendoscopic resection of lesions.

**Conclusion**

The neuroendoscopic resection of brain tumors by NUA was designed to keep the surgical access and thus the collateral damage to the surrounding brain tissue as small as possible. Our systematic literature review showed that in 62.5% a GTR/NTR could be achieved with an overall transient morbidity rate of 32.5% and no permanent morbidity. A careful selection of the patients to be operated by NUA is essential. The instruments for neuroendoscopic tumor resection are continuously evolving, and we expect that the
range of applications for NUA will increase in the future. Therefore, larger studies reporting on NUA use are essential to emphasize its safety and benefits further.

Supplementary Information The online version contains supplementary material available at https://doi.org/10.1007/s10143-022-01837-w.

Author contribution All authors contributed to the study conception and design. Data collection and analysis were performed by Florian Ebel and Jehuda Soleman. The first draft of the manuscript was written by Florian Ebel and all authors commented on previous versions of the manuscript. All authors read and approved the final manuscript.

Funding Open access funding provided by University of Basel

Data availability Not applicable.

Declarations

Ethics approval and consent to participate Not applicable.

Human and animal ethics Not applicable.

Consent for publication Not applicable.

Competing interests The authors declare no competing interests.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not otherwise in a credit line to the material, this article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as the credit is given to the original author(s) and the source. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

References

1. Barber SM, Rangel-Castilla L, Baskin D (2013) Neuroendoscopic resection of intraventricular tumors: a systematic outcomes analysis. Minim Invasive Surg 2013:1–12. https://doi.org/10.1155/2013/898753
2. Oertel J, Krauss JK, Gaab MR (2008) Ultrasonic aspiration in neuroendoscopy: first results with a new tool - Technical note. J Neurosurg 109:908–911. https://doi.org/10.3171/JNS/2008/109/119098
3. Flamm ES, Ransohoff J, Wuchinich D, Broadwin A (1978) Preliminary experience with ultrasonic aspiration in neurosurgery. Neurosurgery 2:240–245. https://doi.org/10.1227/00006123-19780500-00010
4. Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, Shamsiee L, Tetzlaff JM, Akl EA, Brennan SE, Chou R, Glavhill J, Grinnshaw JM, Hrobjartsson A, Lalu MM, Li T, Loder EW, Mayo-Wilson E, McDonald S, McGuinness LA, Stewart LA, Thomas J, Tricco AC, Welch VA, Whiting P, Moher D (2021) The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 372:n71. https://doi.org/10.1136/bmj.n71.MJ
5. Moola S, Munn Z, Tufanaru C, Aromataris E, Sears K, Sfez R, Currie M, Lisy K, Qureshi R, Mattis P, Mu P-F (2020) Chapter 7: systematic reviews of etiology and risk. In: JBI manual for evidence synthesis. JBI, pp 1–6. https://doi.org/10.46658/JBIMES-20-08
6. Cinnali G, Imperato A, Mirone G, Di Martino G, Nicosia G, Ruggero C, Aliberti F, Spennato P (2016) 44th Annual Meeting of International Society for Pediatric Neurosurgery, Kobe, Japan, Oct 23–27, 2016. Child’s Nervous System 32:1957–2040. https://doi.org/10.1007/s00381-016-3209-9
7. García-González O, Hernandez-Ponce P (2015) Endoscopic ultrasonic aspiration for cystic intraventricular craniopharyngioma, 43rd Annual Meeting of International Society for Pediatric Neurosurgery, Izmir, Turkey, Oct 4–8, 2015. Childs Nerv Syst 31:1891–1993. https://doi.org/10.1007/s00381-015-2811-6
8. Cavalcante S, Mendonça, a JN, Dastoli PA, Neto MP, Centeno R (2014) Pure neuroendoscopy for intraventricular tumors using ultrasonic aspiration, 42nd Annual Meeting of the International Society for Pediatric Neurosurgery, Rio De Janeiro, Brazil, Nov 9–13, 2014. Childs Nerv Syst 30:1913–1995. https://doi.org/10.1007/s00381-014-2524-2
9. Cavalcante S, Dastoli P, Nicacio J, Faquini I, Damin S, Ansai R (2010) Pure neuroendoscopy for intraventricular tumors using ultrasonic aspirator, 22nd Congress of European Society for Pediatric Neurosurgery, Belek – Antalya, Turkey, 21–25 April 2010. Childs Nerv Syst 26:545–592. https://doi.org/10.1007/s00381-010-1089-y
10. Cavalcante S, Mendonza J, Chassot A, Jerard DF, Dastoli P, Zymberg ST, Silva NJ (2009) Purely endoscopic approach to the removal of intraventricular tumors. J Neurosurg Pediatr 22:20. https://doi.org/10.3171/2018.1.PEDS1811
11. Lekovic GP, Gonzalez LF, Feiz-Ernan I, Rakate HL (2006) Rekate Endoscopic resection of hypotalamic hamartoma using a novel variable aspiration tissue resector. Neurosurgery 58(ONS166–9); ONS166 9. https://doi.org/10.1227/01.NEU.00003512.87279.69
12. Deopujari C, Karmarkar V, Shaikh S, Mohanty C, Sharma V, Tadghare J, Thareja V (2021) Neuroendoscopy in the surgical management of lateral and third ventricular tumors: looking beyond microneurosurgery. Neurol India 69:1571. https://doi.org/10.4103/0028-3866.333458
13. Selvanathan SK, Kumar R, Goodden J, Tyagi A, Chumas P (2013) Evolving instrumentation for endoscopic tumour removal of CNS tumours. Acta Neurochir 155:135—138. https://doi.org/10.1007/s00701-012-1561-4
14. Tirado-Caballero J, Rivero-Garvia M, Gonzalez-Pombo M, Cárdenas-Ruiz-Valdepeñas E, Kaen A, Márquez-Rivas J (2020) Colloid cyst resection with ultrasonic aspirator during neuroendoscopy. Acta Neurochir 160:1789–1792. https://doi.org/10.1007/s00701-018-3631-8
15. Gerald AWL, Tailor J, Gradil C, Thakur B, Zebian B (2017) Letter to the Editor: Endoscopic resection of intraventricular
choroid plexus papillomas in infants, Journal of Neurosurgery. Pediatrics 19:122–125. https://doi.org/10.3171/2016.5.PEDS16154

18. Cinalli G, Imperato A, Mirone G, di Martino G, Nicosia G, Ruggiero C, Aliberti F, Spennato P (2017) Initial experience with endoscopic ultrasonic aspirator in purely neuroendoscopic removal of intraventricular tumors, Journal of Neurosurgery. Pediatrics 19:325–332. https://doi.org/10.3171/2016.5.PEDS16352

19. Ibáñez-Botella G, Segura M, De Miguel L, Ros B, Arráez MÁ (2019) Purely neuroendoscopic resection of intraventricular tumors with an endoscopic ultrasonic aspirator. Neurosurg Rev 42:973–982

20. Ebel F, Greuter L, Licci M, Guzman R, Soleman J (2021) Endoscopic and endoscopically-assisted resection of intraventricular lesions using a neuroendoscopic ultrasonic aspirator. J Clin Med 10:3889. https://doi.org/10.3390/jcm10173889

21. Spennato P, de Rosa A, Meccariello G, Quaglietta L, Imperato A, Scala MR, Russo C, Cinalli G (2022) Endoscopic ultrasonic aspiration as alternative to more invasive surgery in initial management of optic pathway gliomas in children. Childs Nerv Syst. https://doi.org/10.1007/S00381-022-05515-6

22. Milligan BD, Meyer FB (2010) Morbidity of transcallosal and transcortical approaches to lesions in and around the lateral and third ventricles: a single-institution experience. Neurosurgery 67:1483–1496. https://doi.org/10.1227/NEU.0b013e3181f7eb68

23. Sayehmiri F, Starke RM, Eichberg DG, Ghanikolahloo M, Rahmatian A, Fathi M, Vakili K, Ebrahinzadeh K, Rezaei O, Sadanian M, Mousavinejad SA, Maloumeh EN, Tavasoli HH, Sharifi G (2022) Comparison of microscopic and endoscopic resection of third-ventricular colloid cysts: a systematic review and meta-analysis. Clin Neurol Neurosurg 215:107179. https://doi.org/10.1016/j.clineuro.2022.107179

24. Sheikh AB, Mendelson ZS, Liu JK (2014) Endoscopic versus microsurgical resection of colloid cysts: a systematic review and meta-analysis of 1278 patients. World Neurosurg 82:1187–1197. https://doi.org/10.1016/j.wneu.2014.06.024

25. Forgas P, Geyer CA, Freidberg SR (2001) Characterization of chemical meningitis after neurological surgery. Clin Infect Dis 32:179–185. https://doi.org/10.1086/318471/2/32-2-179-TBL004.GIF

26. Sufianov AA, Gaibov SSK, Sufianov RA (2015) Endoscopic monoportal removal of a choroid plexus papilloma in the posterior third ventricle in a child, Journal of Neurosurgery. Pediatrics 16:107–111. https://doi.org/10.3171/2014.12.PEDS14306

27. Oertel J, Linsler S, Csokonay A, Schroeder HWS, Senger S (2019) Management of severe intraoperative hemorrhage during intraventricular neuroendoscopic procedures: the dry field technique. J Neurosurg 131:931–935. https://doi.org/10.3171/2018.4.JNS172537

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.